probucol has been researched along with Elevated Cholesterol in 176 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study evaluated the efficacy of combined therapy with probucol and cilostazol on endothelial function in silent lacunar cerebral infarcts (SLCI) and mild hypercholesterolemia." | 9.19 | Combined therapeutic effect of probucol and cilostazol on endothelial function in patients with silent cerebral lacunar infarcts and hypercholesterolemia: a preliminary study. ( Hattori, H; Ishihara, M; Nagata, M; Takase, B; Tanaka, Y, 2014) |
| "To clarify whether probucol and statins suppress oxidative stress in diabetic patients, we studied the effects of probucol and the statin atorvastatin on urinary 8-hydroxy-2'deoxyguanosine (8-OHdG) levels in diabetics with hypercholesterolemia." | 9.12 | Probucol and atorvastatin decrease urinary 8-hydroxy-2'-deoxyguanosine in patients with diabetes and hypercholesterolemia. ( Ebisuno, M; Endo, K; Koide, N; Miyashita, Y; Ohira, M; Oyama, T; Saiki, A; Sasaki, H; Shirai, K; Takeyoshi, M, 2006) |
| "The changes in lipoproteins induced by lovastatin (L) and probucol (P) were compared in patients with primary hypercholesterolemia." | 9.07 | [Effects of lovastatin and probucol on lipoprotein fractions in patients with hypercholesterolemia. A Brazilian multicenter study]. ( Forti, N; Ramires, JA, 1991) |
| "A multicenter study was undertaken to compare the effects of lovastatin (given in 4 different dosage regimens) and probucol in patients with severe primary hypercholesterolemia." | 9.06 | A multicenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia. The Lovastatin Study Group IV. ( , 1990) |
| "In order to compare the effects of lovastatin and probucol on lipoprotein profiles, we treated 32 familial hypercholesterolemia (FH) heterozygotes and 26 patients with non-familial hypercholesterolemia for 14 weeks with either probucol (1 g/d) or lovastatin (40-80 mg/d) in a randomized double-blind study." | 9.06 | Comparison of lovastatin and probucol in treatment of familial and non-familial hypercholesterolemia: different effects on lipoprotein profiles. ( Helve, E; Tikkanen, MJ, 1988) |
| "Probucol (1 g per day) was administered in a double-blind crossover trial to 16 patients with familial hypercholesterolemia who had previously been tested for their response to clofibrate." | 9.05 | Usefulness of probucol in treating primary hypercholesterolemia. ( Davignon, J; DuBreuil-Quidoz, S; Enjalbert, M; LeLorier, J; Lussier-Cacan, S, 1980) |
| "The effect of Probucol on serum lipids, lipoproteins and the apoproteins A1, A2 and B was studied in 27 patients with primary hypercholesterolemia." | 9.05 | Probucol in hypercholesterolemia. A double blind study. ( Keller, M; Mordasini, R; Riesen, WF, 1980) |
| "The current study was designed to investigate whether combined use of probucol (an anti-oxidant agent) with cilostazol (a platelet aggregation inhibitor) would increase the inhibitory effect of statins (a lipid-lowering agent) on atherosclerosis in moderately hypercholesterolemic rabbits." | 7.81 | Combined use of probucol and cilostazol with atorvastatin attenuates atherosclerosis in moderately hypercholesterolemic rabbits. ( Bai, L; Chen, Y; Fan, J; Gao, S; Guan, H; Li, Y; Lin, Y; Liu, E; Sun, L; Wang, Y; Zhao, S; Zhu, N, 2015) |
| "This study suggests that probucol inhibits the initiation of atherosclerosis by reducing monocyte adherence and infiltration into the subintima." | 7.79 | Probucol inhibits the initiation of atherosclerosis in cholesterol-fed rabbits. ( Fan, J; Keyamura, Y; Kohashi, M; Koyama, T; Niimi, M; Nozako, M; Yasufuku, R; Yoshikawa, T, 2013) |
| " In the present study, we investigated the beneficial effects of combinatorial therapy with probucol and cilostazol on focal cerebral ischemia with hypercholesterolemia." | 7.77 | Combinatorial effect of probucol and cilostazol in focal ischemic mice with hypercholesterolemia. ( Bae, SS; Choi, BT; Hong, KW; Kim, JH; Kim, YD; Park, KP; Park, SH; Shin, HK, 2011) |
| " We hypothesized that pitavastatin restores vascular function by modulating oxidative stress through the activation of Cu/ZnSOD and PPAR-gamma in hypercholesterolemia." | 7.73 | Comparative effects of pitavastatin and probucol on oxidative stress, Cu/Zn superoxide dismutase, PPAR-gamma, and aortic stiffness in hypercholesterolemia. ( Fukai, T; Itoh, S; Kawahara, S; Matsuzaki, M; Tanaka, M; Umeji, K; Umemoto, S, 2006) |
| "We report a patient who experienced a reversible prolongation of the QT interval and episodes of syncope while receiving probucol." | 7.69 | Probucol-induced QT prolongation and syncope. ( Ito, M; Ohtsuka, E; Oribe, K; Oribe, M; Seita, M; Tamura, M; Ueki, Y, 1994) |
| "In nonhuman primates (Macaca nemestrina) treated with the antioxidant probucol during diet-induced hypercholesterolemia, intimal lesion area in the thoracic aorta was decreased, with increased resistance of plasma LDL to oxidation." | 7.69 | Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. II. Cellular composition and proliferation. ( Chait, A; Chang, MY; Raines, EW; Ross, R; Sasahara, M, 1995) |
| "A time-dependent change in the cholesterol-lowering effect of probucol has been evaluated in 20 subjects with elevated cholesterol." | 7.68 | Time-dependent change in the effect of probucol in subjects with elevated cholesterol. ( Ebihara, A; Fujimura, A; Ohashi, K, 1992) |
| "Long-term treatment with probucol induced marked regression of xanthoma in patients with both homozygous and heterozygous familial hypercholesterolemia despite a substantial accompanying decrease in high-density lipoprotein (HDL) cholesterol." | 7.67 | Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyperHDL2 cholesterolemia with abnormal cholesteryl ester transfer. ( Funahashi, T; Matsuzawa, Y; Tarui, S; Yamamoto, A; Yamashita, S, 1988) |
| "Carotid atherosclerosis is a strong, independent predictor of morbidity and mortality in patients with coronary heart disease (CHD)." | 6.70 | Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). ( Hayashi, J; Kashiwagi, S; Kinukawa, N; Koyanagi, S; Maeda, N; Sawayama, Y; Shimizu, C; Tatsukawa, M, 2002) |
| "Post-transplant hypercholesterolemia is featured with abnormalities in very low-density lipoprotein (VLDL) metabolism." | 6.69 | Effect of probucol on hypercholesterolemia in renal transplant patients. ( Endo, T; Horii, A; Kamata, K; Kobayashi, N; Nakamura, M; Okubo, M; Sato, K; Takeuchi, Y; Tsukamoto, Y, 1999) |
| "Both simvastatin doses were significantly more effective than probucol in improving the plasma lipid profile." | 6.66 | Effects of simvastatin and probucol in hypercholesterolemia (Simvastatin Multicenter Study Group II). ( Alexander, S; Cook, TJ; Mantell, G; Pietro, DA; Staggers, JE, 1989) |
| "Probucol was given in the dose of 1 g and cholestyramine in the dose of 16 g per day in 3 different sequences: Probucol, Cholestyramine, Probucol + Cholestyramine; Probucol + Cholestyramine, Probucol, Cholestyramine; Cholestyramine, Probucol + Cholestyramine, Probucol." | 6.66 | Probucol and cholestyramine combination in the treatment of severe hypercholesterolemia. ( Bonfiglioli, D; Branchi, A; Cabrini, E; Pogliaghi, I; Sommariva, D; Tirrito, M, 1986) |
| "Colestipol is a safe, effective, cholesterol-lowering, bile-acid sequestrant that lowers low-density-lipoprotein (LDL) and total plasma cholesterol levels without consistently affecting high-density-lipoprotein (HDL) cholesterol levels." | 6.36 | Colestipol and probucol: treatment of primary and familial hypercholesterolemia and amelioration of atherosclerosis. ( Glueck, CJ, 1982) |
| " Recently, a new microemulsion formulation of CyA(Neoral) has been developed and used preferably because of a more stable bioavailability than an oily formulation(Sandimmun)." | 5.31 | [Effect of probucol on the blood concentration of cyclosporin A in patients with nephrotic syndrome: a case study with a microemulsion formulation (Neoral)]. ( Inui, K; Muso, E; Ono, T; Wakasugi, H; Yoshimoto, M, 2002) |
| "Treatment with probucol (500 mg/day) or pravastatin (10 mg/day) reduced mean plasma total cholesterol concentrations by 24% (p < 0." | 5.29 | Effects of probucol and pravastatin on plasma lipids, activities of postheparin lipoprotein lipase, and lecithin cholesterol acyltransferase and apo A-I containing lipoproteins with and without apo A-II in patients with moderate hypercholesterolemia. ( Ishikawa, T; Kagami, A; Manabe, M; Mochizuki, K; Moriguchi, EH; Nagano, M; Sakamoto, T; Tada, N, 1993) |
| "Probucol was administered to half of the 16 monkeys 14 wk after starting the hypercholesterolemic diet, and was given daily until they were sacrificed after 11 mos." | 5.29 | Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. I. Is the extent of atherosclerosis related to resistance of LDL to oxidation? ( Carew, TE; Chait, A; Raines, EW; Ross, R; Sasahara, M; Steinberg, D; Wahl, PW, 1994) |
| "Probucol was ineffective in altering this cholesterol-induced increase in enzyme activity except in Group III where it increased the activity of GSH-Px." | 5.29 | Effects of probucol on hypercholesterolemia-induced changes in antioxidant enzymes. ( Kalra, J; Mantha, SV; Prasad, K, 1996) |
| "The lovastatin-alone regimen was well tolerated, whereas addition of colestipol caused subjective side effects in many patients." | 5.28 | Long-term maintenance of therapeutic response to lovastatin in patients with familial and non-familial hypercholesterolemia: a 3-year follow-up. ( Helve, E; Karjalainen, K; Ojala, JP; Tarkkanen, A; Tikkanen, MJ, 1990) |
| "Probucol is a lipid-lowering drug with a well-known antioxidant action." | 5.28 | Effectiveness of probucol in reducing plasma low-density lipoprotein cholesterol oxidation in hypercholesterolemia. ( Bargalló, MT; Casals, I; LaVille, A; Masana, L; Plana, N; Solà, R, 1991) |
| "This study evaluated the efficacy of combined therapy with probucol and cilostazol on endothelial function in silent lacunar cerebral infarcts (SLCI) and mild hypercholesterolemia." | 5.19 | Combined therapeutic effect of probucol and cilostazol on endothelial function in patients with silent cerebral lacunar infarcts and hypercholesterolemia: a preliminary study. ( Hattori, H; Ishihara, M; Nagata, M; Takase, B; Tanaka, Y, 2014) |
| "To clarify whether probucol and statins suppress oxidative stress in diabetic patients, we studied the effects of probucol and the statin atorvastatin on urinary 8-hydroxy-2'deoxyguanosine (8-OHdG) levels in diabetics with hypercholesterolemia." | 5.12 | Probucol and atorvastatin decrease urinary 8-hydroxy-2'-deoxyguanosine in patients with diabetes and hypercholesterolemia. ( Ebisuno, M; Endo, K; Koide, N; Miyashita, Y; Ohira, M; Oyama, T; Saiki, A; Sasaki, H; Shirai, K; Takeyoshi, M, 2006) |
| "The changes in lipoproteins induced by lovastatin (L) and probucol (P) were compared in patients with primary hypercholesterolemia." | 5.07 | [Effects of lovastatin and probucol on lipoprotein fractions in patients with hypercholesterolemia. A Brazilian multicenter study]. ( Forti, N; Ramires, JA, 1991) |
| "In order to compare the effects of lovastatin and probucol on lipoprotein profiles, we treated 32 familial hypercholesterolemia (FH) heterozygotes and 26 patients with non-familial hypercholesterolemia for 14 weeks with either probucol (1 g/d) or lovastatin (40-80 mg/d) in a randomized double-blind study." | 5.06 | Comparison of lovastatin and probucol in treatment of familial and non-familial hypercholesterolemia: different effects on lipoprotein profiles. ( Helve, E; Tikkanen, MJ, 1988) |
| "A multicenter study was undertaken to compare the effects of lovastatin (given in 4 different dosage regimens) and probucol in patients with severe primary hypercholesterolemia." | 5.06 | A multicenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia. The Lovastatin Study Group IV. ( , 1990) |
| "A variety of double-blind studies have compared the efficacy of hydroxymethylglutaryl coenzyme A reductase inhibitors (lovastatin and simvastatin) with that of control agents (cholestyramine, fibrates and probucol) in patients with type IIA or IIB primary hypercholesterolemia." | 5.06 | Hydroxymethylglutaryl coenzyme A reductase inhibitors as monotherapy in the treatment of hypercholesterolemia. ( Shapiro, DR; Walker, JF, 1990) |
| "The effect of Probucol on serum lipids, lipoproteins and the apoproteins A1, A2 and B was studied in 27 patients with primary hypercholesterolemia." | 5.05 | Probucol in hypercholesterolemia. A double blind study. ( Keller, M; Mordasini, R; Riesen, WF, 1980) |
| "Probucol (1 g per day) was administered in a double-blind crossover trial to 16 patients with familial hypercholesterolemia who had previously been tested for their response to clofibrate." | 5.05 | Usefulness of probucol in treating primary hypercholesterolemia. ( Davignon, J; DuBreuil-Quidoz, S; Enjalbert, M; LeLorier, J; Lussier-Cacan, S, 1980) |
| "Administration of probucol to 23 patients with familial xanthomatotic hypercholesterolaemia reduced the serum cholesterol level during the 9-month study by 9%, while in 15 patients with less severe hypercholesterolaemia the decrease was on an average 15%." | 5.04 | Treatment of severe and mild hypercholesterolaemia with probucol and neomycin. ( Miettinen, TA; Toivonen, I, 1975) |
| "We have shown that probucol-induced HDL deficiency impairs the ability of established lesions to regress in response to reversal of the genetic hypercholesterolemia in Apoe knockout mice." | 3.88 | HDL is essential for atherosclerotic lesion regression in Apoe knockout mice by bone marrow Apoe reconstitution. ( Hoekstra, M; Lendvai, Z; van der Sluis, RJ; Van Eck, M; Verwilligen, RAF; Wever, R, 2018) |
| "The current study was designed to investigate whether combined use of probucol (an anti-oxidant agent) with cilostazol (a platelet aggregation inhibitor) would increase the inhibitory effect of statins (a lipid-lowering agent) on atherosclerosis in moderately hypercholesterolemic rabbits." | 3.81 | Combined use of probucol and cilostazol with atorvastatin attenuates atherosclerosis in moderately hypercholesterolemic rabbits. ( Bai, L; Chen, Y; Fan, J; Gao, S; Guan, H; Li, Y; Lin, Y; Liu, E; Sun, L; Wang, Y; Zhao, S; Zhu, N, 2015) |
| "This study suggests that probucol inhibits the initiation of atherosclerosis by reducing monocyte adherence and infiltration into the subintima." | 3.79 | Probucol inhibits the initiation of atherosclerosis in cholesterol-fed rabbits. ( Fan, J; Keyamura, Y; Kohashi, M; Koyama, T; Niimi, M; Nozako, M; Yasufuku, R; Yoshikawa, T, 2013) |
| " In the present study, we investigated the beneficial effects of combinatorial therapy with probucol and cilostazol on focal cerebral ischemia with hypercholesterolemia." | 3.77 | Combinatorial effect of probucol and cilostazol in focal ischemic mice with hypercholesterolemia. ( Bae, SS; Choi, BT; Hong, KW; Kim, JH; Kim, YD; Park, KP; Park, SH; Shin, HK, 2011) |
| " We hypothesized that pitavastatin restores vascular function by modulating oxidative stress through the activation of Cu/ZnSOD and PPAR-gamma in hypercholesterolemia." | 3.73 | Comparative effects of pitavastatin and probucol on oxidative stress, Cu/Zn superoxide dismutase, PPAR-gamma, and aortic stiffness in hypercholesterolemia. ( Fukai, T; Itoh, S; Kawahara, S; Matsuzaki, M; Tanaka, M; Umeji, K; Umemoto, S, 2006) |
| "Inhibitors of the key enzyme of cholesterol biosynthesis beta-hydroxy-beta-methylglutaryl-coenzyme A reductase (statins) decrease cholesterol content in atherogenic low-density lipoproteins in patients with coronary heart disease and hypercholesterolemia, but inhibited biosynthesis of ubiquinone Q10 protecting low-density lipoproteins from free radical oxidation." | 3.71 | Intensification of free radical oxidation of low-density lipoproteins in the plasma of patients with ischemic heart disease receiving beta-hydroxy-beta-methylglutaryl-coenzyme A reductase inhibitor cerivastatin and inhibition of low-density lipoprotein pe ( Belenkov, YN; Konovalova, GG; Kotkina, TI; Kukharchuk, VV; Lankin, VZ; Medvedeva, NV; Tikhaze, AK; Tutunov, VS, 2002) |
| " To clarify the mechanisms underlying vascular dysfunction and oxidative stress in hypercholesterolemia, we compared the effects of antioxidant probucol with those of pravastatin on aortic stiffness, phenotypic modulation, oxidative stress, and NAD(P)H oxidase essential subunit p22(phox) expression in aortic medial SM cells of cholesterol-fed rabbits by using color image analysis of immunostained sections." | 3.71 | Importance of NAD(P)H oxidase-mediated oxidative stress and contractile type smooth muscle myosin heavy chain SM2 at the early stage of atherosclerosis. ( Aoyagi, S; Fujii, T; Hiromoto, M; Itoh, S; Matsuzaki, M; Tanaka, M; Toma, Y; Tomochika, Y; Umemoto, S, 2002) |
| "The therapeutic effect of probucol on hypercholesterolemia in cyclosporine A (CyA)-treated renal transplant patients was prospectively studied." | 3.70 | Effect of probucol on serum lipoprotein and apoprotein profiles in renal transplant patients. ( Endo, T; Horii, A; Kamata, K; Kobayashi, N; Kumano, K; Okubo, M; Sato, K; Takeuchi, Y; Tsukamoto, Y, 1998) |
| "A 62-year-old man with old myocardial infarction and familial hypercholesterolemia was treated by both probucol and low-density lipoprotein (LDL) apheresis." | 3.70 | Long-term effect of low-density lipoprotein apheresis in a patient with heterozygous familial hypercholesterolemia: follow-up study using coronary angiography. ( Arakawa, K; Jimi, S; Naito, S; Nii, T; Okabe, M; Saku, K; Shirai, K; Takeda, Y, 1998) |
| "In nonhuman primates (Macaca nemestrina) treated with the antioxidant probucol during diet-induced hypercholesterolemia, intimal lesion area in the thoracic aorta was decreased, with increased resistance of plasma LDL to oxidation." | 3.69 | Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. II. Cellular composition and proliferation. ( Chait, A; Chang, MY; Raines, EW; Ross, R; Sasahara, M, 1995) |
| "We report a patient who experienced a reversible prolongation of the QT interval and episodes of syncope while receiving probucol." | 3.69 | Probucol-induced QT prolongation and syncope. ( Ito, M; Ohtsuka, E; Oribe, K; Oribe, M; Seita, M; Tamura, M; Ueki, Y, 1994) |
| " In the present study we examined whether lipid-soluble antioxidants, probucol and vitamin E, could inhibit renal injury in rats with chronic puromycin aminonucleoside (PA) nephrosis and dietary hypercholesterolemia by protecting lipoproteins from oxidation." | 3.69 | Dietary antioxidant inhibits lipoprotein oxidation and renal injury in experimental focal segmental glomerulosclerosis. ( Chung, HK; Jeong, JY; Kim, BC; Kim, YS; Lee, HS; Zhang, YZ, 1997) |
| "Probucol treatment has been evaluated in 140 patients with hypercholesterolemia attending a single Lipid Clinic, in an attempt to identify the relations between lipid/lipoprotein responses and patient characteristics." | 3.69 | Clinical evaluation of probucol in hypercholesteremia: individual lipoprotein responses and inhibitory effect on carotid atherosclerosis progression. ( Baldassarre, D; Brusoni, B; Franceschini, G; Peruzzotti, G; Sirtori, CR, 1997) |
| "A time-dependent change in the cholesterol-lowering effect of probucol has been evaluated in 20 subjects with elevated cholesterol." | 3.68 | Time-dependent change in the effect of probucol in subjects with elevated cholesterol. ( Ebihara, A; Fujimura, A; Ohashi, K, 1992) |
| "An assessment has been made regarding the changes of the particles of lipoprotein A-I without A-II (Lp A-I) and lipoprotein A-I with A-II (LpA-I/A-II) which correspond to HDL subfraction isolated by the use of anti-apo A-I and A-II antibody affinity columns in order to quantitatively and qualitatively investigate the change of HDL caused by administration of probucol and pravastatin which are therapeutic drugs for hypercholesterolemia." | 3.68 | [Separation of high density lipoprotein (HDL) using anti-apo A-I, apo A-II immuno-affinity chromatography to evaluate the effects of probucol]. ( Hino, K; Ishikawa, T; Kagami, A; Manabe, M; Mochizuki, K; Sakamoto, T; Satoh, N; Tada, N, 1991) |
| "Eight patients with primary hypercholesterolemia were treated with probucol for 17 weeks." | 3.68 | Effects of probucol on plasma lipids, lipoproteins and parameters of high density lipoprotein metabolism. ( Albers, HW; Barnhart, RL; Chi, EM; Combs, KA; Harmony, JA; Jackson, RL; Lamkin, G; Stein, EA; Wetterau, JR, 1992) |
| "Despite probucol's capacity to induce regression of tendinous xanthomata and reduce whole plasma and LDL cholesterol (LDL-C) in patients with hypercholesterolemia, its therapeutic use in the United States has been limited because of concern about its HDL-lowering effects." | 3.68 | Probucol treatment in hypercholesterolemic patients: effects on lipoprotein composition, HDL particle size, and cholesteryl ester transfer. ( Bagdade, JD; Kaufman, D; Ritter, MC; Subbaiah, PV, 1990) |
| "The QT, QTc, QS2 intervals, pre-ejection period-left ventricular ejection time ratios and serum lipoprotein levels were measured in 8 patients with primary hypercholesterolemia before and after a 3-month therapy with probucol, 1 g/day." | 3.67 | The effects of probucol on QT/QS2 relation and systolic time intervals. ( Fenyvesi, T; László, Z; Littmann, L; Romics, L, 1988) |
| "Long-term treatment with probucol induced marked regression of xanthoma in patients with both homozygous and heterozygous familial hypercholesterolemia despite a substantial accompanying decrease in high-density lipoprotein (HDL) cholesterol." | 3.67 | Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyperHDL2 cholesterolemia with abnormal cholesteryl ester transfer. ( Funahashi, T; Matsuzawa, Y; Tarui, S; Yamamoto, A; Yamashita, S, 1988) |
| "Ten men with hypercholesterolemia were treated sequentially with a fat-modified diet, a diet plus probucol (1 Gm/day), and a diet plus probucol plus cholestyramine (16 Gm/day)." | 3.66 | Synergistic effects of probucol and cholestyramine to lower serum cholesterol. ( Boyden, TW; Totman, L, 1981) |
| "Carotid atherosclerosis is a strong, independent predictor of morbidity and mortality in patients with coronary heart disease (CHD)." | 2.70 | Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). ( Hayashi, J; Kashiwagi, S; Kinukawa, N; Koyanagi, S; Maeda, N; Sawayama, Y; Shimizu, C; Tatsukawa, M, 2002) |
| "Post-transplant hypercholesterolemia is featured with abnormalities in very low-density lipoprotein (VLDL) metabolism." | 2.69 | Effect of probucol on hypercholesterolemia in renal transplant patients. ( Endo, T; Horii, A; Kamata, K; Kobayashi, N; Nakamura, M; Okubo, M; Sato, K; Takeuchi, Y; Tsukamoto, Y, 1999) |
| "Bezafibrate was administered at either 200 mg." | 2.68 | High-density lipoprotein and apolipoprotein A-I deficiency induced by combination therapy with probucol and bezafibrate. ( Arakawa, K; Bai, H; Hirata, K; Jimi, S; Liu, R; Saku, K; Sasaki, N; Zhang, B, 1995) |
| "Probucol was not found to effect progression regression of femoral atherosclerosis significantly as assessed by quantitative arteriography." | 2.68 | The effect of probucol on low density lipoprotein oxidation and femoral atherosclerosis. ( Elinder, LS; Holme, I; Johansson, J; Mölgaard, J; Nilsson, J; Nilsson, S; Olsson, AG; Regnström, J; Walldius, G, 1996) |
| "Both simvastatin doses were significantly more effective than probucol in improving the plasma lipid profile." | 2.66 | Effects of simvastatin and probucol in hypercholesterolemia (Simvastatin Multicenter Study Group II). ( Alexander, S; Cook, TJ; Mantell, G; Pietro, DA; Staggers, JE, 1989) |
| "Probucol was given in the dose of 1 g and cholestyramine in the dose of 16 g per day in 3 different sequences: Probucol, Cholestyramine, Probucol + Cholestyramine; Probucol + Cholestyramine, Probucol, Cholestyramine; Cholestyramine, Probucol + Cholestyramine, Probucol." | 2.66 | Probucol and cholestyramine combination in the treatment of severe hypercholesterolemia. ( Bonfiglioli, D; Branchi, A; Cabrini, E; Pogliaghi, I; Sommariva, D; Tirrito, M, 1986) |
| " The daily dosage of probucol was 1 g divided into two 500 mg doses." | 2.65 | [A long-term (9 years) clinical study of the safety and efficacy of probucol, and an analysis of morbidity and mortality rates (author's transl)]. ( Cerimelle, BJ; Martz, BL; Taylor, HA; Tedeschi, RE, 1980) |
| "Monitored clinical studies conducted in 1133 patients, involving 3928 patient years of experience with probucol, have shown that it is an effective cholesterol lowering agent and is well tolerated during long term administration (some patients treated for as long as nine years)." | 2.65 | Safety and effectiveness of probucol as a cholesterol lowering agent. ( Cerimele, BJ; Martz, BL; Taylor, HA; Tedeschi, RE, 1982) |
| " In 32 patients with Type II HL and 12 with Type IIB HL, statistically significant reduction in mean serum cholesterol levels occurred within two weeks and persisted throughout two years of therapy at constant dosage (500 mg." | 2.64 | Effect of probucol in hyperlipidemic patients during two years of administration. ( Parsons, WB, 1978) |
| " Probucol, in a dosage of 500 mg twice daily, produced a 10% or greater reduction in serum cholesterol levels in all 11 patients." | 2.64 | Probucol: a new cholesterol-lowering drug effective in patients with type II hyperlipoproteinemia. ( Mason, DT; Price, J; Salel, AF; Sodhi, HS; Zelis, R, 1976) |
| "Niacin was the most efficient agent for reducing low-density lipoprotein cholesterol levels, having an average cost over 5 years of $139 per percent reduction in low-density lipoprotein cholesterol level." | 2.38 | Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management. ( Eisenberg, JM; Glick, H; Jacobson, TA; Kinosian, B; Koffer, H; Schulman, KA; Willian, MK, 1990) |
| "Probucol is a lipid-regulating agent structurally dissimilar to other known agents, with a unique pharmacodynamic and clinical profile." | 2.38 | Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia. ( Brogden, RN; Buckley, MM; Goa, KL; Price, AH, 1989) |
| "Probucol is a widely used serum-cholesterol lowering drug." | 2.37 | Mode of hypocholesterolemic action of probucol in animals and man. ( Beynen, AC, 1987) |
| "The surgical treatment of hypercholesterolemia and the treatment of homozygous and other forms of hypercholesterolemia are also detailed." | 2.36 | Treatment of hypercholesterolemia. ( Kane, JP; Malloy, MJ, 1982) |
| "Colestipol is a safe, effective, cholesterol-lowering, bile-acid sequestrant that lowers low-density-lipoprotein (LDL) and total plasma cholesterol levels without consistently affecting high-density-lipoprotein (HDL) cholesterol levels." | 2.36 | Colestipol and probucol: treatment of primary and familial hypercholesterolemia and amelioration of atherosclerosis. ( Glueck, CJ, 1982) |
| "Probucol has anti-oxidant properties as well as cholesterol-lowering effects and may affect soluble thrombomodulin (sTM)." | 1.35 | Effect of the anti-oxidant probucol on soluble thrombomodulin (sTM) in hypercholesterolemic rabbits. ( Hong, SC; Liu, Q; Wu, ZH; Zhao, SP, 2008) |
| "Probucol is known to be a potent hypolipidemic drug to regress xanthoma formation and carotid atherosclerosis in conjunction with a marked reduction in HDL-cholesterol levels." | 1.34 | Effect of probucol on HDL metabolism and class B type I scavenger receptor (SR-BI) expression in the liver of hypercholesterolemic rabbits. ( Hong, SC; Wu, ZH; Zhao, SP, 2007) |
| " Recently, a new microemulsion formulation of CyA(Neoral) has been developed and used preferably because of a more stable bioavailability than an oily formulation(Sandimmun)." | 1.31 | [Effect of probucol on the blood concentration of cyclosporin A in patients with nephrotic syndrome: a case study with a microemulsion formulation (Neoral)]. ( Inui, K; Muso, E; Ono, T; Wakasugi, H; Yoshimoto, M, 2002) |
| "We have established a reproducible stenosis model in hypercholesterolemic hamsters, and the process of arterial stenosis by thrombus or neointima was studied and compared with that in normal hamsters." | 1.31 | Characterization of simple and reproducible vascular stenosis model in hypercholesterolemic hamsters. ( Abe, A; Kozawa, O; Matsuno, H; Niwa, M; Takiguchi, Y; Uematsu, T, 2001) |
| " Calculated bioavailability following oral administration of cyclosporin A decreased by 33% with the treatment of probucol." | 1.30 | Decrease in oral bioavailability of cyclosporin A by coadministration of probucol in rats. ( Fujimura, A; Sakamoto, K; Sugimoto, K, 1997) |
| "Probucol, a drug commonly employed for treatment of hypercholesterolemia, has antioxidant properties and inhibits oxidation of low density lipoproteins in vitro." | 1.30 | Probucol improves endothelial-dependent relaxation and decreases vascular superoxide production in cholesterol-fed rabbits. ( Fukai, T; Harrison, DG; Inoue, N; Nishida, K; Ohara, Y, 1998) |
| " Silybin was not so effective as silymarin suggesting that either other constituent(s) of silymarin may be responsible for its anticholesterolemic effect or the bioavailability of silybin alone might be lower than that of silybin as a compound of silymarin." | 1.30 | Silymarin inhibits the development of diet-induced hypercholesterolemia in rats. ( Krecman, V; Simánek, V; Skottová, N; Ulrichová, J; Walterová, D, 1998) |
| "A decision to treat hyperlipidemias would be based on the assumption that such disorders lead to accelerated atherogenesis and ultimately to cardiac dysfunction." | 1.30 | Lack of left ventricular dysfunction associated with sustained exposure to hyperlipidemia following lung transplantation. ( Kesten, S; Maurer, J; Mayne, L; Scavuzzo, M, 1997) |
| "Probucol treatment results in an increase in plasma concentrations of cholesteryl ester transfer protein (CETP) which may account, in part, for the effects of this agent on plasma concentrations of HDL cholesterol." | 1.29 | Adipose tissue cholesteryl ester transfer protein mRNA in response to probucol treatment: cholesterol and species dependence. ( Huerta, P; Marcel, YL; McPherson, R; Nancoo, D; Quinet, EM; Tall, AR, 1993) |
| "Treatment with probucol (500 mg/day) or pravastatin (10 mg/day) reduced mean plasma total cholesterol concentrations by 24% (p < 0." | 1.29 | Effects of probucol and pravastatin on plasma lipids, activities of postheparin lipoprotein lipase, and lecithin cholesterol acyltransferase and apo A-I containing lipoproteins with and without apo A-II in patients with moderate hypercholesterolemia. ( Ishikawa, T; Kagami, A; Manabe, M; Mochizuki, K; Moriguchi, EH; Nagano, M; Sakamoto, T; Tada, N, 1993) |
| "Probucol was administered to half of the 16 monkeys 14 wk after starting the hypercholesterolemic diet, and was given daily until they were sacrificed after 11 mos." | 1.29 | Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. I. Is the extent of atherosclerosis related to resistance of LDL to oxidation? ( Carew, TE; Chait, A; Raines, EW; Ross, R; Sasahara, M; Steinberg, D; Wahl, PW, 1994) |
| "Probucol was ineffective in altering this cholesterol-induced increase in enzyme activity except in Group III where it increased the activity of GSH-Px." | 1.29 | Effects of probucol on hypercholesterolemia-induced changes in antioxidant enzymes. ( Kalra, J; Mantha, SV; Prasad, K, 1996) |
| "The lovastatin-alone regimen was well tolerated, whereas addition of colestipol caused subjective side effects in many patients." | 1.28 | Long-term maintenance of therapeutic response to lovastatin in patients with familial and non-familial hypercholesterolemia: a 3-year follow-up. ( Helve, E; Karjalainen, K; Ojala, JP; Tarkkanen, A; Tikkanen, MJ, 1990) |
| "Probucol treatment in hypercholesterolemic patients promotes the transfer of cholesteryl esters from high-density-lipoproteins (HDL) to lower-density lipoproteins." | 1.28 | In vitro activity of probucol on cholesteryl ester transport. ( Chiesa, G; Franceschini, G; Sirtori, CR, 1990) |
| "There are indications that treatment of hypercholesterolemia by means of drugs reduce risk of atherosclerosis in patients with increased concentrations of atherogenic lipoproteins." | 1.28 | [Drug therapy of hypercholesterolemia. Treatment of hypercholesterolemia in adults--a Norwegian therapeutic program 1988]. ( Blomhoff, JP; Ose, L; Torsvik, H, 1989) |
| "Probucol is a lipid-lowering drug with a well-known antioxidant action." | 1.28 | Effectiveness of probucol in reducing plasma low-density lipoprotein cholesterol oxidation in hypercholesterolemia. ( Bargalló, MT; Casals, I; LaVille, A; Masana, L; Plana, N; Solà, R, 1991) |
| "Probucol is a drug that lowers both LDL and HDL cholesterol levels." | 1.27 | Lipoprotein fractions and receptors: a role for probucol? ( Bilheimer, DW, 1986) |
| " These findings suggest that there is an optimum dosage of probucol to lower LDL + VLDL cholesterol and the atherogenic index, and that the actual optimum dosage for the beneficial effect depends on blood lipid levels or types of hyperlipidemia." | 1.26 | Effect of probucol on serum lipoprotein levels in normal and dyslipoproteinemic mice. ( Abiko, Y; Nakayasu, T; Tawara, K; Tomikawa, M, 1981) |
| " Repeated administration of probucol to healthy volunteers showed good correlation between dosage and blood levels." | 1.26 | [Plasma levels of probucol in man after single and repeated oral doses (author's transl)]. ( Heeg, JF; Tachizawa, H, 1980) |
| "Probucol seems to be a non hepatotoxic drug and induces a decrease of lithogenic index of bile." | 1.26 | [Probucol: mechanism of action (author's transl)]. ( Infante, R, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 83 (47.16) | 18.7374 |
| 1990's | 64 (36.36) | 18.2507 |
| 2000's | 19 (10.80) | 29.6817 |
| 2010's | 10 (5.68) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| van der Sluis, RJ | 1 |
| Verwilligen, RAF | 1 |
| Lendvai, Z | 1 |
| Wever, R | 1 |
| Hoekstra, M | 1 |
| Van Eck, M | 1 |
| Niimi, M | 1 |
| Keyamura, Y | 1 |
| Nozako, M | 1 |
| Koyama, T | 1 |
| Kohashi, M | 1 |
| Yasufuku, R | 1 |
| Yoshikawa, T | 1 |
| Fan, J | 3 |
| Takase, B | 1 |
| Nagata, M | 1 |
| Hattori, H | 1 |
| Tanaka, Y | 1 |
| Ishihara, M | 1 |
| Kim, JH | 2 |
| Hong, KW | 2 |
| Bae, SS | 2 |
| Shin, YI | 1 |
| Choi, BT | 2 |
| Shin, HK | 2 |
| Wang, Y | 2 |
| Bai, L | 2 |
| Lin, Y | 2 |
| Guan, H | 2 |
| Zhu, N | 2 |
| Chen, Y | 2 |
| Li, Y | 2 |
| Gao, S | 2 |
| Zhao, S | 2 |
| Liu, E | 2 |
| Sun, L | 1 |
| Yakushiji, E | 1 |
| Ayaori, M | 1 |
| Nishida, T | 1 |
| Shiotani, K | 1 |
| Takiguchi, S | 1 |
| Nakaya, K | 1 |
| Uto-Kondo, H | 1 |
| Ogura, M | 1 |
| Sasaki, M | 1 |
| Yogo, M | 1 |
| Komatsu, T | 1 |
| Lu, R | 1 |
| Yokoyama, S | 1 |
| Ikewaki, K | 1 |
| Yamashita, S | 4 |
| Bujo, H | 1 |
| Arai, H | 1 |
| Harada-Shiba, M | 1 |
| Matsui, S | 1 |
| Fukushima, M | 1 |
| Saito, Y | 1 |
| Kita, T | 3 |
| Matsuzawa, Y | 3 |
| Park, SH | 1 |
| Kim, YD | 1 |
| Park, KP | 1 |
| Fang, L | 1 |
| Green, SR | 1 |
| Baek, JS | 1 |
| Lee, SH | 1 |
| Ellett, F | 1 |
| Deer, E | 1 |
| Lieschke, GJ | 1 |
| Witztum, JL | 3 |
| Tsimikas, S | 1 |
| Miller, YI | 1 |
| Moreira, EL | 1 |
| de Oliveira, J | 1 |
| Dutra, MF | 1 |
| Santos, DB | 1 |
| Gonçalves, CA | 1 |
| Goldfeder, EM | 1 |
| de Bem, AF | 1 |
| Prediger, RD | 1 |
| Aschner, M | 1 |
| Farina, M | 1 |
| Nagai, Y | 2 |
| Yanagi, K | 1 |
| Takemura, K | 1 |
| Lankin, VZ | 2 |
| Tikhaze, AK | 1 |
| Konovalova, GG | 1 |
| Tutunov, VS | 1 |
| Medvedeva, NV | 1 |
| Kotkina, TI | 1 |
| Kukharchuk, VV | 1 |
| Belenkov, YN | 1 |
| Wakasugi, H | 1 |
| Yoshimoto, M | 1 |
| Ono, T | 1 |
| Muso, E | 1 |
| Inui, K | 1 |
| Nakao, A | 1 |
| Nosaka, K | 1 |
| Imaki, H | 1 |
| Noiri, E | 1 |
| Toda, A | 1 |
| Doi, K | 1 |
| Suzuki, Y | 1 |
| Fujita, T | 1 |
| Kimura, S | 1 |
| Hong, SC | 3 |
| Zhao, SP | 3 |
| Wu, ZH | 3 |
| Endo, K | 1 |
| Miyashita, Y | 1 |
| Sasaki, H | 1 |
| Ebisuno, M | 1 |
| Ohira, M | 1 |
| Saiki, A | 1 |
| Koide, N | 1 |
| Oyama, T | 1 |
| Takeyoshi, M | 1 |
| Shirai, K | 2 |
| Sawayama, Y | 2 |
| Maeda, S | 2 |
| Ohnishi, H | 1 |
| Okada, K | 1 |
| Hayashi, J | 2 |
| Xu, G | 1 |
| Li, XS | 1 |
| Huang, WQ | 1 |
| Huang, H | 1 |
| Umeji, K | 1 |
| Umemoto, S | 2 |
| Itoh, S | 2 |
| Tanaka, M | 2 |
| Kawahara, S | 1 |
| Fukai, T | 2 |
| Matsuzaki, M | 2 |
| Liu, Q | 1 |
| Bateson, MC | 2 |
| Miettinen, TA | 5 |
| Huttunen, JK | 2 |
| Strandberg, T | 2 |
| Naukkarinen, V | 2 |
| Mattila, S | 2 |
| Kumlin, T | 2 |
| Troendle, G | 1 |
| Guerigian, J | 1 |
| Sobel, S | 1 |
| Johnson, M | 1 |
| Donatelli, L | 2 |
| Dujovne, CA | 3 |
| Chernoff, SB | 2 |
| Krehbiel, P | 2 |
| Jackson, B | 1 |
| DeCoursey, S | 1 |
| Taylor, H | 1 |
| Kesäniemi, YA | 1 |
| Grundy, SM | 2 |
| Santos, Rde O | 1 |
| Moriguchi, Y | 1 |
| McCaughan, D | 2 |
| Tomikawa, M | 1 |
| Nakayasu, T | 1 |
| Tawara, K | 1 |
| Abiko, Y | 1 |
| Quintão, EC | 1 |
| Maranhão, RC | 1 |
| Tedeschi, RE | 2 |
| Martz, BL | 3 |
| Taylor, HA | 2 |
| Cerimelle, BJ | 1 |
| Glueck, CJ | 1 |
| Kane, JP | 2 |
| Malloy, MJ | 1 |
| Cerimele, BJ | 1 |
| Mordasini, R | 2 |
| Riesen, W | 1 |
| Oster, P | 1 |
| Riva, G | 1 |
| Kuusi, T | 1 |
| Davignon, J | 2 |
| Lussier-Cacan, S | 2 |
| Dubreuil-Quidoz, S | 2 |
| LeLorier, J | 2 |
| Opplt, JJ | 1 |
| Chick, LL | 1 |
| Opplt, MA | 1 |
| Magill, P | 1 |
| Whiting, C | 1 |
| Hammett, F | 1 |
| Glick, I | 1 |
| Miller, NE | 2 |
| Lewis, B | 2 |
| Schonfeld, G | 1 |
| Witztum, J | 1 |
| Basich, P | 1 |
| Cortese, C | 1 |
| Marenah, CB | 1 |
| Pasquali, R | 1 |
| Melchionda, N | 1 |
| Parenti, M | 1 |
| Cavazzini, MG | 1 |
| Biso, P | 1 |
| Baraldi, G | 1 |
| Sorrenti, G | 1 |
| De Benedittis, G | 1 |
| Labò, G | 1 |
| Boyden, TW | 1 |
| Totman, L | 1 |
| Herdová, J | 1 |
| Zapletalová, J | 1 |
| Fiabane, AM | 1 |
| Clarke, A | 1 |
| Bouchier, IA | 1 |
| Mishkel, MA | 1 |
| Crowther, SM | 1 |
| Duarte, GM | 1 |
| Lavall, M | 1 |
| da Cunha, GP | 1 |
| da Cunha, CL | 1 |
| Riesen, WF | 1 |
| Keller, M | 1 |
| Infante, R | 1 |
| Heeg, JF | 1 |
| Tachizawa, H | 1 |
| Roach, L | 1 |
| Botha, A | 1 |
| Joffe, BI | 1 |
| Baker, SG | 1 |
| Shires, R | 1 |
| Seftel, HC | 1 |
| Enjalbert, M | 1 |
| Chang, MY | 1 |
| Sasahara, M | 2 |
| Chait, A | 2 |
| Raines, EW | 2 |
| Ross, R | 2 |
| Saku, K | 4 |
| Zhang, B | 3 |
| Jimi, S | 2 |
| Bai, H | 2 |
| Hirata, K | 3 |
| Sasaki, N | 2 |
| Liu, R | 3 |
| Arakawa, K | 4 |
| Yamamoto, K | 2 |
| Fukuda, N | 2 |
| Shiroi, S | 2 |
| Shiotsuki, Y | 2 |
| Nagata, Y | 2 |
| Tani, T | 2 |
| Sakai, T | 2 |
| Johansson, J | 6 |
| Olsson, AG | 6 |
| Bergstrand, L | 2 |
| Elinder, LS | 3 |
| Nilsson, S | 5 |
| Erikson, U | 4 |
| Mölgaard, J | 4 |
| Holme, I | 3 |
| Walldius, G | 7 |
| Hådell, K | 3 |
| Mølgaard, J | 1 |
| Parker, RA | 1 |
| Sabrah, T | 1 |
| Cap, M | 1 |
| Gill, BT | 1 |
| Anderson, TJ | 1 |
| Meredith, IT | 1 |
| Yeung, AC | 1 |
| Frei, B | 1 |
| Selwyn, AP | 1 |
| Ganz, P | 1 |
| Hattori, M | 1 |
| Ito, K | 1 |
| Kawaguchi, H | 1 |
| Yamaguchi, Y | 2 |
| Kaijser, L | 2 |
| Lassvik, C | 2 |
| Tamura, M | 1 |
| Ueki, Y | 1 |
| Ohtsuka, E | 1 |
| Oribe, M | 1 |
| Seita, M | 1 |
| Oribe, K | 1 |
| Ito, M | 1 |
| Carew, TE | 1 |
| Steinberg, D | 2 |
| Wahl, PW | 1 |
| Kitagawa, S | 1 |
| Imaizumi, N | 1 |
| Kunitomo, M | 1 |
| Fujiwara, M | 1 |
| Okura, Y | 1 |
| Ohya, Y | 1 |
| Kumamoto, K | 1 |
| Abe, I | 1 |
| Tsubota, Y | 1 |
| Fujishima, M | 1 |
| Regnström, J | 3 |
| Nilsson, J | 3 |
| Schäfer-Elinder, L | 1 |
| Moelgaard, J | 1 |
| Carlson, LA | 3 |
| Kagami, A | 2 |
| Ishikawa, T | 2 |
| Tada, N | 2 |
| Sakamoto, T | 2 |
| Mochizuki, K | 2 |
| Nagano, M | 1 |
| Moriguchi, EH | 1 |
| Manabe, M | 2 |
| Ikeda, T | 1 |
| Quinet, EM | 1 |
| Huerta, P | 1 |
| Nancoo, D | 1 |
| Tall, AR | 1 |
| Marcel, YL | 1 |
| McPherson, R | 2 |
| Moroe, K | 1 |
| Mantha, SV | 1 |
| Kalra, J | 1 |
| Prasad, K | 1 |
| Del Rio, M | 1 |
| Chulia, T | 1 |
| Ruiz, E | 1 |
| Tejerina, T | 1 |
| Sugimoto, K | 1 |
| Sakamoto, K | 1 |
| Fujimura, A | 2 |
| Lee, HS | 1 |
| Jeong, JY | 1 |
| Kim, BC | 1 |
| Kim, YS | 1 |
| Zhang, YZ | 1 |
| Chung, HK | 1 |
| Kesten, S | 1 |
| Mayne, L | 1 |
| Scavuzzo, M | 1 |
| Maurer, J | 1 |
| Jorge, PA | 1 |
| Baldassarre, D | 1 |
| Franceschini, G | 2 |
| Peruzzotti, G | 1 |
| Brusoni, B | 1 |
| Sirtori, CR | 2 |
| Okubo, M | 2 |
| Horii, A | 2 |
| Kamata, K | 2 |
| Takeuchi, Y | 2 |
| Tsukamoto, Y | 2 |
| Kobayashi, N | 2 |
| Sato, K | 2 |
| Kumano, K | 1 |
| Endo, T | 2 |
| Krecman, V | 1 |
| Skottová, N | 1 |
| Walterová, D | 1 |
| Ulrichová, J | 1 |
| Simánek, V | 1 |
| Inoue, N | 1 |
| Ohara, Y | 1 |
| Harrison, DG | 1 |
| Nishida, K | 1 |
| Takeda, Y | 1 |
| Okabe, M | 1 |
| Nii, T | 1 |
| Naito, S | 1 |
| Miida, T | 1 |
| Yamaguchi, T | 1 |
| Tsuda, T | 1 |
| Okada, M | 1 |
| Donetti, E | 1 |
| Soma, MR | 1 |
| Barberi, L | 1 |
| Paoletti, R | 1 |
| Fumagalli, R | 1 |
| Roma, P | 1 |
| Catapano, AL | 1 |
| Harada, N | 1 |
| Kashiwagi, A | 1 |
| Nishio, Y | 1 |
| Kikkawa, R | 1 |
| Kodama, N | 1 |
| Otani, H | 1 |
| Yamada, Y | 1 |
| Mune, M | 1 |
| Yukawa, S | 1 |
| Nakamura, M | 1 |
| Fruebis, J | 1 |
| Silvestre, M | 1 |
| Shelton, D | 1 |
| Napoli, C | 1 |
| Palinski, W | 1 |
| Pfuetze, KD | 1 |
| Chin-Dusting, JP | 1 |
| Shaw, JA | 1 |
| Kimura, Y | 1 |
| Uchiyama, S | 1 |
| Matsuno, H | 1 |
| Kozawa, O | 1 |
| Niwa, M | 1 |
| Abe, A | 2 |
| Takiguchi, Y | 1 |
| Uematsu, T | 1 |
| Schwenke, DC | 1 |
| Behr, SR | 1 |
| Shimizu, C | 1 |
| Maeda, N | 1 |
| Tatsukawa, M | 1 |
| Kinukawa, N | 1 |
| Koyanagi, S | 1 |
| Kashiwagi, S | 1 |
| Hiromoto, M | 1 |
| Toma, Y | 1 |
| Tomochika, Y | 1 |
| Aoyagi, S | 1 |
| Fujii, T | 1 |
| Salel, AF | 1 |
| Zelis, R | 1 |
| Sodhi, HS | 1 |
| Price, J | 1 |
| Mason, DT | 1 |
| Murphy, BF | 1 |
| Toivonen, I | 2 |
| Heel, RC | 1 |
| Brogden, RN | 2 |
| Speight, TM | 1 |
| Avery, GS | 1 |
| Parsons, WB | 1 |
| Forti, N | 2 |
| Diament, J | 1 |
| Giannini, SD | 1 |
| Rapado, A | 1 |
| Castrillo, JM | 1 |
| Díaz-Curiel, M | 1 |
| Nash, DT | 2 |
| Kisanuki, A | 1 |
| Asada, Y | 1 |
| Hatakeyama, K | 1 |
| Hayashi, T | 1 |
| Sumiyoshi, A | 1 |
| Bocan, TM | 1 |
| Mueller, SB | 1 |
| Brown, EQ | 1 |
| Uhlendorf, PD | 1 |
| Mazur, MJ | 1 |
| Newton, RS | 1 |
| Ohashi, K | 1 |
| Ebihara, A | 1 |
| Baumstark, MW | 2 |
| Arístegui, R | 1 |
| Zöller, T | 1 |
| Frey, I | 2 |
| Berg, A | 2 |
| Keul, J | 2 |
| Reaven, PD | 1 |
| Parthasarathy, S | 2 |
| Beltz, WF | 1 |
| Florkowski, CM | 1 |
| Cramb, R | 1 |
| Wetterau, JR | 1 |
| Combs, KA | 1 |
| Albers, HW | 1 |
| Lamkin, G | 1 |
| Stein, EA | 1 |
| Barnhart, RL | 1 |
| Chi, EM | 1 |
| Jackson, RL | 1 |
| Harmony, JA | 1 |
| Hino, K | 1 |
| Satoh, N | 1 |
| Ramires, JA | 1 |
| Liu, K | 1 |
| Lupanov, VP | 1 |
| Liakishev, AA | 1 |
| Revenko, VM | 1 |
| Masana, L | 1 |
| Bargalló, MT | 1 |
| Plana, N | 1 |
| LaVille, A | 1 |
| Casals, I | 1 |
| Solà, R | 1 |
| Marcel, Y | 1 |
| Halle, M | 1 |
| Schulman, KA | 1 |
| Kinosian, B | 1 |
| Jacobson, TA | 1 |
| Glick, H | 1 |
| Willian, MK | 1 |
| Koffer, H | 1 |
| Eisenberg, JM | 1 |
| Walker, JF | 1 |
| Shapiro, DR | 1 |
| Nagano, Y | 1 |
| Bagdade, JD | 1 |
| Kaufman, D | 1 |
| Ritter, MC | 1 |
| Subbaiah, PV | 1 |
| Ojala, JP | 1 |
| Helve, E | 3 |
| Karjalainen, K | 1 |
| Tarkkanen, A | 1 |
| Tikkanen, MJ | 4 |
| Chiesa, G | 1 |
| Howard, PA | 1 |
| Okuno, M | 1 |
| Noma, A | 1 |
| Ishii, K | 1 |
| Pietro, DA | 1 |
| Alexander, S | 1 |
| Mantell, G | 1 |
| Staggers, JE | 1 |
| Cook, TJ | 1 |
| Buckley, MM | 1 |
| Goa, KL | 1 |
| Price, AH | 1 |
| Ose, L | 1 |
| Blomhoff, JP | 1 |
| Torsvik, H | 1 |
| Shankar, R | 1 |
| Sallis, JD | 1 |
| Stanton, H | 1 |
| Thomson, R | 1 |
| Yoshino, G | 1 |
| Kazumi, T | 1 |
| Uenoyama, R | 1 |
| Inui, A | 1 |
| Kasama, T | 1 |
| Iwatani, I | 1 |
| Iwai, M | 1 |
| Yokono, K | 1 |
| Otsuki, M | 1 |
| Baba, S | 1 |
| Strandberg, TE | 1 |
| Vanhanen, H | 1 |
| Hunninghake, DB | 1 |
| Schwartz, CJ | 1 |
| Stenport, G | 1 |
| Fonteles, MC | 1 |
| Costa e Forti, A | 1 |
| de Freitas, MT | 1 |
| Nikkilä, EA | 2 |
| Cohen, L | 1 |
| Morgan, J | 1 |
| Funahashi, T | 1 |
| Yamamoto, A | 1 |
| Tarui, S | 1 |
| Romics, L | 1 |
| Littmann, L | 1 |
| László, Z | 1 |
| Fenyvesi, T | 1 |
| Havel, RJ | 1 |
| Valeri, A | 1 |
| Gelfand, J | 1 |
| Blum, C | 1 |
| Appel, GB | 1 |
| Beynen, AC | 2 |
| Bilheimer, DW | 1 |
| DiPalma, JR | 1 |
| Eder, HA | 1 |
| Sommariva, D | 1 |
| Bonfiglioli, D | 1 |
| Tirrito, M | 1 |
| Pogliaghi, I | 1 |
| Branchi, A | 1 |
| Cabrini, E | 1 |
| Young, SG | 1 |
| Pittman, RC | 1 |
| Polachek, AA | 1 |
| Katz, HM | 1 |
| Sack, J | 1 |
| Selig, J | 1 |
| Littman, ML | 1 |
| Harris, RS | 1 |
| Gilmore, HR | 1 |
| Bricker, LA | 1 |
| Kiem, IM | 1 |
| Rubin, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Investigate Effect on Mean IMT of Probucol And/or CilosTazol in Patients With Coronary Heart dIsease Taking HMGCoA Reductase Inhibitor Therapy: A Randomized, Multicenter, Multinational Study[NCT01291641] | Phase 4 | 342 participants (Actual) | Interventional | 2011-03-31 | Completed | ||
| [NCT00005681] | 0 participants | Observational | 1989-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
25 reviews available for probucol and Elevated Cholesterol
| Article | Year |
|---|---|
[Treatment of high blood cholesterol in patients with coronary heart disease].
Topics: Anion Exchange Resins; Bezafibrate; Clinical Trials as Topic; Coronary Disease; Humans; Hydroxymethy | 1994 |
[Treatment of high blood cholesterol in patients with coronary heart disease].
Topics: Anion Exchange Resins; Cholesterol, LDL; Cholestyramine Resin; Clinical Trials as Topic; Coronary Di | 2003 |
[Pharmacology of probucol. I].
Topics: Adult; Aged; Animals; Anticholesteremic Agents; Chemical Phenomena; Chemistry; Cholesterol; Clofibra | 1984 |
[Pharmacology of probucol. II].
Topics: Animals; Cholesterol; Dogs; Drug Evaluation; Female; Heart; Heart Rate; Humans; Hypercholesterolemia | 1984 |
Recommendations for treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriosclerosis.
Topics: Cholesterol; Clofibrate; Coronary Disease; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperl | 1984 |
Colestipol and probucol: treatment of primary and familial hypercholesterolemia and amelioration of atherosclerosis.
Topics: Arteriosclerosis; Cholesterol; Colestipol; Drug Therapy, Combination; Humans; Hypercholesterolemia; | 1982 |
Treatment of hypercholesterolemia.
Topics: Cholestyramine Resin; Colestipol; Drug Therapy, Combination; Heterozygote; Homozygote; Humans; Hyper | 1982 |
[Endothelium, lipids and atherosclerosis].
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Endocytosis; Endothelium, Vascular; Foam Cells; | 1997 |
Probucol.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Apolipoproteins E; Arteriosclerosis; Cardiovascular | 2000 |
Lipids and atherosclerosis: clinical management of hypercholesterolaemia.
Topics: Arteriosclerosis; Cholestyramine Resin; Clinical Trials as Topic; Humans; Hydroxymethylglutaryl-CoA | 2001 |
[Hyperlipidemia and cerebrovascular disease].
Topics: Anticholesteremic Agents; Apolipoproteins; Cerebral Infarction; Cerebrovascular Disorders; Cholester | 2001 |
Diet and drug synergism in treatment of hypercholesterolemia.
Topics: Adult; Cholesterol, Dietary; Fats, Unsaturated; Female; Humans; Hypercholesterolemia; Hyperlipidemia | 1978 |
Probucol: a review of its pharmacological properties and therapeutic use in patients with hypercholesterolaemia.
Topics: Animals; Arteriosclerosis; Clofibrate; Dogs; Humans; Hypercholesterolemia; Hyperlipidemias; Kinetics | 1978 |
[Therapeutic orientation in the hyperlipidemias].
Topics: Cholestyramine Resin; Dextrothyroxine; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic | 1979 |
Approaches to the management of hypercholesterolaemia.
Topics: Bezafibrate; Bile Acids and Salts; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperchol | 1992 |
[Advance in drug treatment of primary and familial hypercholesterolemia].
Topics: Animals; Cholestyramine Resin; Drugs, Chinese Herbal; Humans; Hypercholesterolemia; Hyperlipoprotein | 1991 |
[Mechanisms of anti-atherogenic effect of probucol and the prospects of its clinical use].
Topics: Arteriosclerosis; Cholesterol; Cholesterol, LDL; Cholesterol, VLDL; Drug Evaluation; Humans; Hyperch | 1991 |
Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Clinical Trials as Topic; Colestipol; Cost-Benefit A | 1990 |
Management of hyperlipidemia of kidney disease.
Topics: Anticholesteremic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolem | 1990 |
Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia.
Topics: Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Phenols; Probucol | 1989 |
Probucol in long-term treatment of hypercholesterolemia.
Topics: Animals; Humans; Hypercholesterolemia; Phenols; Probucol; Time Factors | 1988 |
The probucol experience: a review of the past and a look at the future.
Topics: Animals; Antioxidants; Arteriosclerosis; Drug Evaluation; Drug Evaluation, Preclinical; Humans; Hype | 1988 |
Treatment of familial and non-familial hypercholesterolaemia: a review of HMG-CoA reductase inhibitors and probucol.
Topics: Arteriosclerosis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hype | 1987 |
Treatment of hypercholesterolemia.
Topics: Animals; Cholestyramine Resin; Clofibrate; Colestipol; Cricetinae; Dogs; Drug Therapy, Combination; | 1986 |
Mode of hypocholesterolemic action of probucol in animals and man.
Topics: Animals; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Humans; Hypercholestero | 1987 |
45 trials available for probucol and Elevated Cholesterol
| Article | Year |
|---|---|
Combined therapeutic effect of probucol and cilostazol on endothelial function in patients with silent cerebral lacunar infarcts and hypercholesterolemia: a preliminary study.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiovascular Agents; Cholinergic Antagonists; Cilostazol; Drug T | 2014 |
Probucol and atorvastatin decrease urinary 8-hydroxy-2'-deoxyguanosine in patients with diabetes and hypercholesterolemia.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adult; Anticholesteremic Agents; Antioxidants; Atorvastatin; Biomarkers | 2006 |
Effect of probucol on elderly hypercholesterolemic patients in the FAST study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticholesteremic Agents; Atherosclerosis; Cardiovascul | 2006 |
Low-dose colestipol plus probucol for hypercholesterolemia.
Topics: Adult; Cholesterol; Clinical Trials as Topic; Colestipol; Constipation; Diarrhea; Double-Blind Metho | 1984 |
[Effect of probucol on blood lipids].
Topics: Aged; Cholesterol; Clinical Trials as Topic; Female; Humans; Hypercholesterolemia; Male; Middle Aged | 1982 |
Nine years of treatment with probucol.
Topics: Arrhythmias, Cardiac; Cholesterol; Clinical Trials as Topic; Double-Blind Method; Electrocardiograph | 1982 |
[Action of probucol in the control of hypercholesterolemia].
Topics: Adult; Cholesterol; Clinical Trials as Topic; Diet; Female; Humans; Hypercholesterolemia; Male; Phen | 1980 |
[A long-term (9 years) clinical study of the safety and efficacy of probucol, and an analysis of morbidity and mortality rates (author's transl)].
Topics: Adult; Cholesterol; Clinical Trials as Topic; Coronary Disease; Female; Follow-Up Studies; Humans; H | 1980 |
The long-term effects of probucol on serum lipid levels.
Topics: Cholesterol; Clinical Trials as Topic; Double-Blind Method; Electrocardiography; Humans; Hypercholes | 1981 |
Safety and effectiveness of probucol as a cholesterol lowering agent.
Topics: Adult; Cholesterol; Clinical Trials as Topic; Double-Blind Method; Humans; Hypercholesterolemia; Myo | 1982 |
[Behavior of high-density lipoproteins in drug lipid-lowering treatment].
Topics: Adult; Apoproteins; Bezafibrate; Cholesterol; Cholesterol, HDL; Clofibric Acid; Colestipol; Humans; | 1982 |
Probucol in hypercholesterolemia. A double blind study.
Topics: Adult; Aged; Apolipoproteins; Cholesterol; Double-Blind Method; Female; Humans; Hypercholesterolemia | 1980 |
Usefulness of probucol in treating primary hypercholesterolemia.
Topics: Adult; Aged; Cholesterol; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Phenols; Probucol | 1980 |
High-density lipoprotein and apolipoprotein A-I deficiency induced by combination therapy with probucol and bezafibrate.
Topics: Adult; Aged; Apolipoproteins; Bezafibrate; Drug Combinations; Female; Humans; Hypercholesterolemia; | 1995 |
Lowering of HDL2b by probucol partly explains the failure of the drug to affect femoral atherosclerosis in subjects with hypercholesterolemia. A Probucol Quantitative Regression Swedish Trial (PQRST) Report.
Topics: Apolipoprotein A-I; Arteriosclerosis; Cholesterol, HDL; Cholestyramine Resin; Female; Femoral Artery | 1995 |
Probucol treatment decreases serum concentrations of diet-derived antioxidants.
Topics: Antioxidants; Cholestyramine Resin; Diet; Female; Humans; Hypercholesterolemia; Male; Middle Aged; P | 1995 |
The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion.
Topics: Acetylcholine; Anticholesteremic Agents; Antioxidants; Cholestyramine Resin; Coronary Artery Disease | 1995 |
The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion.
Topics: Acetylcholine; Anticholesteremic Agents; Antioxidants; Cholestyramine Resin; Coronary Artery Disease | 1995 |
The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion.
Topics: Acetylcholine; Anticholesteremic Agents; Antioxidants; Cholestyramine Resin; Coronary Artery Disease | 1995 |
The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion.
Topics: Acetylcholine; Anticholesteremic Agents; Antioxidants; Cholestyramine Resin; Coronary Artery Disease | 1995 |
The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST).
Topics: Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Double-Blind Method; Fem | 1994 |
Combined therapy with probucol and pravastatin in hypercholesterolaemia. One year follow-up study.
Topics: Adult; Aged; Aged, 80 and over; Apolipoproteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Do | 1993 |
The role of lipids and antioxidative factors for development of atherosclerosis. The Probucol Quantitative Regression Swedish Trial (PQRST).
Topics: Aged; Antioxidants; Arteriosclerosis; Cholesterol; Dietary Fats; Double-Blind Method; Female; Humans | 1993 |
The effect of probucol on low density lipoprotein oxidation and femoral atherosclerosis.
Topics: Adult; Angiography; Anticholesteremic Agents; Arteriosclerosis; Disease Progression; Female; Femoral | 1996 |
High prebeta1-HDL levels in hypercholesterolemia are maintained by probucol but reduced by a low-cholesterol diet.
Topics: Aged; Anticholesteremic Agents; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, | 1998 |
Effects of cholesterol-lowering treatments on oxidative modification of plasma intermediate density lipoprotein plus low density lipoprotein fraction in Type 2 diabetic patients.
Topics: Anticholesteremic Agents; Apolipoproteins B; Blood Glucose; Body Mass Index; Cholesterol; Cholestero | 1999 |
Effect of probucol on hypercholesterolemia in renal transplant patients.
Topics: Adult; Anticholesteremic Agents; Apolipoprotein A-I; Cholesterol; Cholesterol, HDL; Cholesterol, LDL | 1999 |
Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST).
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Carotid Artery Diseases; Carotid Artery, C | 2002 |
Probucol: a new cholesterol-lowering drug effective in patients with type II hyperlipoproteinemia.
Topics: Cholesterol; Clinical Trials as Topic; Depression, Chemical; Drug Evaluation; Female; Humans; Hyperc | 1976 |
Probucol (Lorelco) in treatment of hyperlipemia.
Topics: Cholesterol; Clinical Trials as Topic; Humans; Hypercholesterolemia; Hyperlipidemias; Lipoproteins, | 1977 |
Treatment of severe and mild hypercholesterolaemia with probucol and neomycin.
Topics: Clinical Trials as Topic; Feces; Humans; Hypercholesterolemia; Lipoproteins, LDL; Lipoproteins, VLDL | 1975 |
Effect of probucol in hyperlipidemic patients during two years of administration.
Topics: Adult; Aged; Cholesterol; Clinical Trials as Topic; Female; Humans; Hypercholesterolemia; Hyperlipid | 1978 |
Probucol, a new cholesterol lowering drug.
Topics: Anticholesteremic Agents; Cholesterol; Clinical Trials as Topic; Drug Evaluation; Humans; Hyperchole | 1975 |
Treatment of severe and mild hypercholesterolaemia with probucol and neomycin..
Topics: Cholesterol; Clinical Trials as Topic; Humans; Hypercholesterolemia; Neomycin; Phenols; Probucol; Tr | 1975 |
Effect of probucol dosage on plasma lipid and lipoprotein levels and on protection of low density lipoprotein against in vitro oxidation in humans.
Topics: Cholesterol, HDL; Female; Humans; Hypercholesterolemia; Lipid Peroxidation; Lipids; Lipoproteins; Li | 1992 |
[Effects of lovastatin and probucol on lipoprotein fractions in patients with hypercholesterolemia. A Brazilian multicenter study].
Topics: Analysis of Variance; Brazil; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Fe | 1991 |
Hydroxymethylglutaryl coenzyme A reductase inhibitors as monotherapy in the treatment of hypercholesterolemia.
Topics: Bezafibrate; Cholestyramine Resin; Double-Blind Method; Gemfibrozil; Humans; Hydroxymethylglutaryl-C | 1990 |
Changes in atheroma volume estimated from digitized femoral arteriograms.
Topics: Algorithms; Angiography, Digital Subtraction; Arteriosclerosis; Double-Blind Method; Female; Femoral | 1990 |
A multicenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia. The Lovastatin Study Group IV.
Topics: Adult; Aged; Apolipoproteins; Cholesterol; Cholesterol, LDL; Double-Blind Method; Drug Evaluation; F | 1990 |
Effects of simvastatin and probucol in hypercholesterolemia (Simvastatin Multicenter Study Group II).
Topics: Adult; Aged; Anticholesteremic Agents; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-Co | 1989 |
Comparison of lovastatin and probucol in treatment of familial and non-familial hypercholesterolemia: different effects on lipoprotein profiles.
Topics: Apolipoproteins; Clinical Trials as Topic; Genetic Carrier Screening; Humans; Hypercholesterolemia; | 1988 |
Development of femoral atherosclerosis in hypercholesterolemic patients during treatment with cholestyramine and probucol/placebo: Probucol Quantitative Regression Swedish Trial (PQRST): a status report.
Topics: Arteriosclerosis; Cholestyramine Resin; Clinical Trials as Topic; Combined Modality Therapy; Drug Th | 1988 |
[Probucol in patients with diabetes mellitus type II with hypercholesterolemia].
Topics: Cholesterol; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Humans; Hyper | 1987 |
Controlled studies of the efficacy and safety of combined probucol-colestipol therapy.
Topics: Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Colestipol; Double-Blind Method; Drug | 1986 |
Treatment of the hyperlipidemia of the nephrotic syndrome: a controlled trial.
Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Colestipol; Female; Human | 1986 |
Probucol and cholestyramine combination in the treatment of severe hypercholesterolemia.
Topics: Adult; Aged; Blood Pressure; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Drug Therapy, | 1986 |
Probucol in the long-term treatment of hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Body Weight; Cholesterol; Clinical Trials as Topic; Drug Hypersensi | 1973 |
Long-term oral administration of probucol (4,4'-(isopropylidenedithio) bis(2,6-di-t-butylphenol)) (DH-581) in the management of hypercholesterolemia.
Topics: Administration, Oral; Adult; Anticholesteremic Agents; Chemical Phenomena; Chemistry; Clinical Trial | 1974 |
106 other studies available for probucol and Elevated Cholesterol
| Article | Year |
|---|---|
HDL is essential for atherosclerotic lesion regression in Apoe knockout mice by bone marrow Apoe reconstitution.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Bone Marrow; Bone Marrow Transplantation; Cholesterol, | 2018 |
Probucol inhibits the initiation of atherosclerosis in cholesterol-fed rabbits.
Topics: Animals; Anticholesteremic Agents; Aorta; Atherosclerosis; Atorvastatin; Cell Adhesion; Cholesterol; | 2013 |
Probucol plus cilostazol attenuate hypercholesterolemia‑induced exacerbation in ischemic brain injury via anti-inflammatory effects.
Topics: Animals; Anti-Inflammatory Agents; Astrocytes; Brain Injuries; Brain Ischemia; CD11b Antigen; Cerebr | 2014 |
Demonstration of an add-on effect of probucol and cilostazol on the statin-induced anti-atherogenic effects.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Cilostazol; Drug Therapy, Combinat | 2014 |
Combined use of probucol and cilostazol with atorvastatin attenuates atherosclerosis in moderately hypercholesterolemic rabbits.
Topics: Animals; Aorta; Atherosclerosis; Atorvastatin; Biomarkers; Cilostazol; Drug Therapy, Combination; Hy | 2015 |
Probucol-Oxidized Products, Spiroquinone and Diphenoquinone, Promote Reverse Cholesterol Transport in Mice.
Topics: Androstadienes; Animals; Anticholesteremic Agents; Aorta; Aortic Diseases; Apolipoprotein A-I; Apoli | 2016 |
Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan.
Topics: Adult; Aged; Anticholesteremic Agents; Cardiovascular Diseases; Cohort Studies; Disease-Free Surviva | 2008 |
Combinatorial effect of probucol and cilostazol in focal ischemic mice with hypercholesterolemia.
Topics: Animals; Brain Ischemia; Cerebrovascular Circulation; Cilostazol; Drug Therapy, Combination; Hyperch | 2011 |
In vivo visualization and attenuation of oxidized lipid accumulation in hypercholesterolemic zebrafish.
Topics: Animals; Animals, Genetically Modified; Antibodies, Monoclonal; Anticholesteremic Agents; Blood Vess | 2011 |
Does methylmercury-induced hypercholesterolemia play a causal role in its neurotoxicity and cardiovascular disease?
Topics: Animals; Anticholesteremic Agents; Behavior, Animal; Biomarkers; Cardiovascular Diseases; Cerebellum | 2012 |
Intensification of free radical oxidation of low-density lipoproteins in the plasma of patients with ischemic heart disease receiving beta-hydroxy-beta-methylglutaryl-coenzyme A reductase inhibitor cerivastatin and inhibition of low-density lipoprotein pe
Topics: Antioxidants; Cholesterol; Cholesterol, LDL; Coenzymes; Double-Blind Method; Enzyme Inhibitors; Free | 2002 |
[Effect of probucol on the blood concentration of cyclosporin A in patients with nephrotic syndrome: a case study with a microemulsion formulation (Neoral)].
Topics: Aged; Anticholesteremic Agents; Cyclosporine; Drug Interactions; Drug Monitoring; Drug Therapy, Comb | 2002 |
Effects of probucol on renal function and urinary protein excretion in spontaneously hypercholesterolemic rats fed a normal or high cholesterol diet.
Topics: Animals; Anticholesteremic Agents; Blood Pressure; Cholesterol, Dietary; Dose-Response Relationship, | 2004 |
Probucol up-regulates paraoxonase 1 expression in hepatocytes of hypercholesterolemic rabbits.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Aryldialkylphosphatase; Body Weight; Gene Expressio | 2006 |
[Effect of probucol and losartan on growth factors after balloon angioplasty in rabbits].
Topics: Angioplasty, Balloon; Animals; Anticholesteremic Agents; Coronary Restenosis; Drug Therapy, Combinat | 2006 |
Effect of probucol on HDL metabolism and class B type I scavenger receptor (SR-BI) expression in the liver of hypercholesterolemic rabbits.
Topics: Animals; Anticholesteremic Agents; CD36 Antigens; Cholesterol, HDL; Disease Models, Animal; Hepatocy | 2007 |
Comparative effects of pitavastatin and probucol on oxidative stress, Cu/Zn superoxide dismutase, PPAR-gamma, and aortic stiffness in hypercholesterolemia.
Topics: Animals; Anticholesteremic Agents; Aorta; Elasticity; Enzyme Inhibitors; Hypercholesterolemia; Immun | 2006 |
Effect of the anti-oxidant probucol on soluble thrombomodulin (sTM) in hypercholesterolemic rabbits.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Hypercholesterolemia; Male; Probucol; Rabbits; Thro | 2008 |
Probucol with cholestyramine.
Topics: Cholestyramine Resin; Drug Synergism; Humans; Hypercholesterolemia; Phenols; Probucol | 1981 |
Lowered HDL cholesterol and incidence of ischaemic heart disease.
Topics: Cholesterol; Cholesterol, HDL; Coronary Disease; Humans; Hypercholesterolemia; Lipoproteins, HDL; Ph | 1981 |
Probucol and the QT interval.
Topics: Electrocardiography; Heart; Humans; Hypercholesterolemia; Phenols; Probucol | 1982 |
Influence of probucol on cholesterol and lipoprotein metabolism in man.
Topics: Adult; Aged; Apolipoproteins; Bile; Cholesterol; Female; Humans; Hypercholesterolemia; Kinetics; Lip | 1984 |
Effect of probucol on serum lipoprotein levels in normal and dyslipoproteinemic mice.
Topics: Animals; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Clofibrate; Dose-Respon | 1981 |
Clinical experience with probucol with special emphasis on mode of action and long-term treatment.
Topics: Cholesterol; Coronary Disease; Electrocardiography; Heart Diseases; Humans; Hypercholesterolemia; Ph | 1982 |
Experience with probucol in the treatment of hypercholesterolemia.
Topics: Cholesterol; Clofibrate; Clofibric Acid; Humans; Hypercholesterolemia; Lipoproteins; Male; Middle Ag | 1982 |
Correlative design of electrophoretic and ultracentrifugal investigation of metabolic effects of probucol.
Topics: Blood Protein Electrophoresis; Coronary Disease; Diet; Electrophoresis, Agar Gel; Humans; Hyperchole | 1982 |
Probucol: effects on the metabolism of low density and high density lipoproteins in moderate hypercholesterolaemia.
Topics: Cholesterol; Humans; Hypercholesterolemia; Kinetics; Lipoproteins, HDL; Lipoproteins, LDL; Phenols; | 1982 |
Probucol further lowers the serum cholesterol of colestipol-treated patients with hypercholesterolemia.
Topics: Adult; Aged; Apoproteins; Cholesterol; Colestipol; Drug Therapy, Combination; Female; Humans; Hyperc | 1982 |
The effects of probucol on plasma lipoproteins in polygenic and familial hypercholesterolaemia.
Topics: Adolescent; Adult; Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diarrhea; Electrocardiogra | 1982 |
[Comparative effect of probucol and clofibrate in patients with primary hypercholesterolemia].
Topics: Adult; Clofibrate; Female; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Male; Middle | 1982 |
Synergistic effects of probucol and cholestyramine to lower serum cholesterol.
Topics: Adult; Aged; Cholesterol; Cholestyramine Resin; Dietary Fats; Drug Synergism; Drug Therapy, Combinat | 1981 |
[Clinical assessment of probucol and its therapeutical effect on hypercholesterolaemia (author's transl)].
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Female; Humans; Hypercholesterolemia; Male; Midd | 1981 |
Probucol and hypercholesterolaemia.
Topics: Adult; Aged; Bile; Cholesterol; Diet; Female; Humans; Hypercholesterolemia; Lipid Metabolism; Male; | 1981 |
Probucol: a weak hypocholesterolemic agent.
Topics: Adult; Double-Blind Method; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Phenols; Probuc | 1981 |
[Effects of probucol on plasma cholesterol and triglyceride levels].
Topics: Adult; Body Weight; Chemical Phenomena; Chemistry; Cholesterol; Hemodynamics; Humans; Hypercholester | 1981 |
[Probucol in the treatment of hypercholesterolemia].
Topics: Adult; Aged; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Phenols; Probucol; Triglycerid | 1981 |
[Probucol: mechanism of action (author's transl)].
Topics: Animals; Bile; Cholesterol; Humans; Hypercholesterolemia; Lipids; Lipoproteins; Liver; Mice; Phenols | 1980 |
[Plasma levels of probucol in man after single and repeated oral doses (author's transl)].
Topics: Administration, Oral; Half-Life; Humans; Hypercholesterolemia; Phenols; Probucol; Time Factors | 1980 |
Probucol treatment and thyroid function tests.
Topics: Adult; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Phenols; Probucol; Thyroid Hormones | 1980 |
Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. II. Cellular composition and proliferation.
Topics: Animals; Anticholesteremic Agents; Aorta; Apolipoproteins B; Arteries; Arteriosclerosis; Cell Divisi | 1995 |
Effect of dietary antioxidants on the susceptibility to hepatic microsomal lipid peroxidation in the rat.
Topics: Animals; Antioxidants; Butylated Hydroxytoluene; Cholesterol; Diet; Fatty Acids; Food, Fortified; Hy | 1995 |
Relation of vascular oxidative stress, alpha-tocopherol, and hypercholesterolemia to early atherosclerosis in hamsters.
Topics: Animals; Antioxidants; Aorta; Arteriosclerosis; Corn Oil; Cricetinae; Diet, Atherogenic; Dose-Respon | 1995 |
Probucol reduces renal injury in the ExHC rat.
Topics: Animals; Cholesterol; Electrophoresis; Food, Fortified; Hypercholesterolemia; Kidney Glomerulus; Lip | 1994 |
Probucol-induced QT prolongation and syncope.
Topics: Atrial Fibrillation; Diltiazem; Electrocardiography; Female; Humans; Hypercholesterolemia; Long QT S | 1994 |
Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol. I. Is the extent of atherosclerosis related to resistance of LDL to oxidation?
Topics: Animals; Aorta, Thoracic; Arteriosclerosis; Cholesterol, Dietary; Hypercholesterolemia; Lipoproteins | 1994 |
Ameliorative effect of dietary probucol on polychlorinated biphenyls-induced hypercholesterolemia and lipid peroxidation in the rat.
Topics: Animals; Cholesterol; Cholesterol, HDL; Diet; Hypercholesterolemia; Lipid Peroxidation; Liver; Male; | 1994 |
Enhancement of aortic cholesterol deposition by dietary linoleic acid in cholesterol-fed mice: an animal model for primary screening of antiatherosclerotic agents.
Topics: Animals; Anticholesteremic Agents; Aorta; Arteriosclerosis; Cholesterol; Cholesterol, Dietary; Desmo | 1993 |
Factors related to QT interval prolongation during probucol treatment.
Topics: Electrocardiography; Female; Humans; Hypercholesterolemia; Long QT Syndrome; Male; Middle Aged; Prob | 1993 |
Choice of cholesterol-lowering drugs.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Clofibrate; Colestipol; Fish Oils; Gemfibrozil; Huma | 1993 |
Effects of probucol and pravastatin on plasma lipids, activities of postheparin lipoprotein lipase, and lecithin cholesterol acyltransferase and apo A-I containing lipoproteins with and without apo A-II in patients with moderate hypercholesterolemia.
Topics: Apolipoprotein A-I; Apolipoprotein A-II; Cholesterol, HDL; Female; Humans; Hypercholesterolemia; Lip | 1993 |
Marked decrease in serum HDL cholesterol levels by combined probucol-pravastatin treatment in hypercholesterolemic NIDDM patients.
Topics: Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Comb | 1993 |
Adipose tissue cholesteryl ester transfer protein mRNA in response to probucol treatment: cholesterol and species dependence.
Topics: Adipose Tissue; Animals; Apolipoproteins E; Carrier Proteins; Cholesterol Ester Transfer Proteins; C | 1993 |
Long-term administration of probucol and QTc interval prolongation.
Topics: Aged; Electrocardiography; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Probucol; Time F | 1993 |
Effects of probucol on hypercholesterolemia-induced changes in antioxidant enzymes.
Topics: Animals; Anticholesteremic Agents; Aorta; Catalase; Cholesterol, Dietary; Dose-Response Relationship | 1996 |
Action of probucol in arteries from normal and hypercholesterolaemic rabbits.
Topics: Animals; Anticholesteremic Agents; Arteries; Arteriosclerosis; Calcium; Calcium Radioisotopes; Chole | 1996 |
Decrease in oral bioavailability of cyclosporin A by coadministration of probucol in rats.
Topics: Administration, Oral; Animals; Anticholesteremic Agents; Biological Availability; Cholesterol; Cross | 1997 |
Dietary antioxidant inhibits lipoprotein oxidation and renal injury in experimental focal segmental glomerulosclerosis.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Cholesterol, Dietary; Diet; Glomerulosclerosis, Foc | 1997 |
Lack of left ventricular dysfunction associated with sustained exposure to hyperlipidemia following lung transplantation.
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Cholestyramine Resin; Echocardiography; Fem | 1997 |
Clinical evaluation of probucol in hypercholesteremia: individual lipoprotein responses and inhibitory effect on carotid atherosclerosis progression.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anticholesteremic Agents; Arteriosclerosis; Ca | 1997 |
Effect of probucol on serum lipoprotein and apoprotein profiles in renal transplant patients.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins; Cholesterol; Fatty Acids, Nonesterified; Female; H | 1998 |
Silymarin inhibits the development of diet-induced hypercholesterolemia in rats.
Topics: Animals; Anticholesteremic Agents; Cholesterol; Cholesterol, Dietary; Cholesterol, HDL; Female; Glut | 1998 |
Probucol improves endothelial-dependent relaxation and decreases vascular superoxide production in cholesterol-fed rabbits.
Topics: Animals; Anticholesteremic Agents; Body Weight; Cholesterol, Dietary; Endothelium, Vascular; Hyperch | 1998 |
Long-term effect of low-density lipoprotein apheresis in a patient with heterozygous familial hypercholesterolemia: follow-up study using coronary angiography.
Topics: Anticholesteremic Agents; Blood Component Removal; Coronary Angiography; Coronary Artery Disease; Fo | 1998 |
Dual effects of the antioxidant agents probucol and carvedilol on proliferative and fatty lesions in hypercholesterolemic rabbits.
Topics: Adrenergic beta-Antagonists; Animals; Anticholesteremic Agents; Antihypertensive Agents; Antioxidant | 1998 |
Involvement of MCP-1 and M-CSF in glomerular foam cell formation in ExHC rats.
Topics: Animals; Anticholesteremic Agents; Chemokine CCL2; Cholesterol, Dietary; Foam Cells; Hypercholestero | 1999 |
Inhibition of VCAM-1 expression in the arterial wall is shared by structurally different antioxidants that reduce early atherosclerosis in NZW rabbits.
Topics: Animals; Antioxidants; Aorta, Thoracic; Arteriosclerosis; Body Weight; Cholesterol, Dietary; Copper; | 1999 |
Characterization of simple and reproducible vascular stenosis model in hypercholesterolemic hamsters.
Topics: Animals; Becaplermin; Blood Flow Velocity; Carotid Arteries; Carotid Artery Thrombosis; Cells, Cultu | 2001 |
Alpha-tocopherol and probucol reduce autoantibody titer to MDA-LDL in hypercholesterolemic rabbits.
Topics: alpha-Tocopherol; Animals; Anticholesteremic Agents; Antioxidants; Aorta; Arteriosclerosis; Autoanti | 2001 |
Importance of NAD(P)H oxidase-mediated oxidative stress and contractile type smooth muscle myosin heavy chain SM2 at the early stage of atherosclerosis.
Topics: Actins; Animals; Anticholesteremic Agents; Antioxidants; Aorta, Thoracic; Arteriosclerosis; Choleste | 2002 |
Drug management of hypercholesterolemia.
Topics: Cholestyramine Resin; Clofibrate; Colestipol; Dextrothyroxine; Humans; Hypercholesterolemia; Nicotin | 1979 |
Use of diet and probucol.
Topics: Child; Cholestyramine Resin; Female; Humans; Hypercholesterolemia; Phenols; Probucol | 1979 |
[Hypolipidemic effects of DH581 during prolonged administration (author's transl)].
Topics: Adolescent; Adult; Aged; Body Weight; Cholesterol; Drug Evaluation; Female; Humans; Hypercholesterol | 1976 |
Contribution of the endothelium to intimal thickening in normocholesterolemic and hypercholesterolemic rabbits.
Topics: Animals; Arteriosclerosis; Cell Division; Disease Models, Animal; Hypercholesterolemia; Immunohistoc | 1992 |
Antiatherosclerotic effects of antioxidants are lesion-specific when evaluated in hypercholesterolemic New Zealand white rabbits.
Topics: Animals; Antioxidants; Aorta; Arteriosclerosis; Ascorbic Acid; Blood Vessels; Cholesterol; Cholester | 1992 |
Time-dependent change in the effect of probucol in subjects with elevated cholesterol.
Topics: Aged; Aged, 80 and over; Cholesterol; Cholesterol, HDL; Female; Humans; Hypercholesterolemia; Male; | 1992 |
Probucol, incorporated into LDL particles in vivo, inhibits generation of lipid peroxides more effectively than endogenous antioxidants alone.
Topics: Antioxidants; Cholesterol; Humans; Hypercholesterolemia; Lipid Peroxides; Lipoproteins, LDL; Male; P | 1992 |
Effects of probucol on plasma lipids, lipoproteins and parameters of high density lipoprotein metabolism.
Topics: Aged; Apolipoproteins; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Fe | 1992 |
[Separation of high density lipoprotein (HDL) using anti-apo A-I, apo A-II immuno-affinity chromatography to evaluate the effects of probucol].
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoprotein A-II; Chromatography, Affinity; Drug Evaluation; Fem | 1991 |
Effectiveness of probucol in reducing plasma low-density lipoprotein cholesterol oxidation in hypercholesterolemia.
Topics: Adult; Aged; Apolipoproteins A; Apolipoproteins B; Cholesterol; Cholesterol, LDL; Female; Humans; Hy | 1991 |
Role of cholesteryl ester transfer protein in reverse cholesterol transport.
Topics: Apolipoproteins E; Biological Transport; Carrier Proteins; Cholesterol; Cholesterol Ester Transfer P | 1991 |
Clinical and therapeutic use of probucol.
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Humans; Hypercholesterolemia; Platelet Aggregation; Plate | 1991 |
[Modified LDL and its physiological significance].
Topics: Animals; Arteriosclerosis; Foam Cells; Humans; Hypercholesterolemia; Lipoproteins, LDL; Probucol; Re | 1990 |
Probucol treatment in hypercholesterolemic patients: effects on lipoprotein composition, HDL particle size, and cholesteryl ester transfer.
Topics: Adult; Aged; Cholesterol Esters; Cholesterol, HDL; Female; Humans; Hypercholesterolemia; Lipids; Lip | 1990 |
Effect of probucol treatment on the susceptibility of low density lipoprotein isolated from hypercholesterolemic patients to become oxidatively modified in vitro.
Topics: Aged; Cells, Cultured; Cholesterol; Cholestyramine Resin; Fatty Acids; Female; Food, Formulated; Hum | 1990 |
Long-term maintenance of therapeutic response to lovastatin in patients with familial and non-familial hypercholesterolemia: a 3-year follow-up.
Topics: Adult; Aged; Cholesterol, LDL; Colestipol; Female; Follow-Up Studies; Humans; Hypercholesterolemia; | 1990 |
In vitro activity of probucol on cholesteryl ester transport.
Topics: Biological Transport; Cholesterol Esters; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Hum | 1990 |
Probucol in hypercholesterolemia.
Topics: Humans; Hypercholesterolemia; Phenols; Probucol | 1989 |
Lack of effect of probucol on serum lipoprotein(a) levels.
Topics: Adult; Aged; Apolipoproteins A; Female; Humans; Hypercholesterolemia; Male; Middle Aged; Phenols; Pr | 1989 |
[Recent trend in the research of hyperlipidemia in Japan. Influence of defective metabolism of low-density lipoprotein on atherosclerosis].
Topics: Arteriosclerosis; Foam Cells; Humans; Hypercholesterolemia; Lipoproteins, LDL; Probucol | 1989 |
[Drug therapy of hypercholesterolemia. Treatment of hypercholesterolemia in adults--a Norwegian therapeutic program 1988].
Topics: Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Niacin; Norway; Probuc | 1989 |
Influence of probucol on early experimental atherogenesis in hypercholesterolemic rats.
Topics: Animals; Arteriosclerosis; Cell Adhesion; Cholesterol; Endothelium, Vascular; Hypercholesterolemia; | 1989 |
Probucol versus eptastatin in hypercholesterolaemic diabetics.
Topics: Cholesterol, HDL; Diabetes Complications; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Mal | 1986 |
Current and new therapy for hypercholesterolemia.
Topics: Anticholesteremic Agents; Colestipol; Gemfibrozil; Humans; Hypercholesterolemia; Lovastatin; Niacin; | 1988 |
Effectiveness of individualized long-term therapy with niacin and probucol in reduction of serum cholesterol.
Topics: Adult; Aged; Arteriosclerosis; Cholesterol; Combined Modality Therapy; Drug Therapy, Combination; Fe | 1988 |
[How do changes in the plasma concentration of HDL induced by probucol operate?].
Topics: Humans; Hypercholesterolemia; Lipoproteins, HDL; Lipoproteins, LDL; Phenols; Probucol | 1988 |
A symposium: Second International Conference on Hypercholesterolemia--examining new data on probucol after a decade of use.
Topics: Animals; Humans; Hypercholesterolemia; Phenols; Probucol | 1988 |
Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyperHDL2 cholesterolemia with abnormal cholesteryl ester transfer.
Topics: Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Cholesterol, HDL; Corneal | 1988 |
The effects of probucol on QT/QS2 relation and systolic time intervals.
Topics: Adult; Arrhythmias, Cardiac; Cardiac Output; Cholesterol; Electrocardiography; Female; Humans; Hyper | 1988 |
Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel.
Topics: Adult; Aged; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Colestipol; Coronary Disease; Diet | 1988 |
Current pharmacologic treatment of elevated serum cholesterol.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Co | 1987 |
Lipoprotein fractions and receptors: a role for probucol?
Topics: Anticholesteremic Agents; Biological Transport; Cholesterol; Cholesterol, Dietary; Cholesterol, HDL; | 1986 |
Lovastatin: cholesterol-lowering agent.
Topics: Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Humans; Hypercholesterolemia; | 1987 |
A symposium: new developments in the treatment of hypercholesterolemia--probucol. Introduction.
Topics: Cholesterol, LDL; Coronary Disease; Humans; Hypercholesterolemia; Lipoproteins, LDL; Phenols; Probuc | 1986 |
A symposium: New developments in the treatment of hypercholesterolemia--probucol. December 7, 1985, New York, New York.
Topics: Humans; Hypercholesterolemia; Hyperlipidemias; Phenols; Probucol | 1986 |
Discrepancies between the outcome of animal and human studies on the mode of action of probucol.
Topics: Animals; Apolipoproteins B; Aryl Hydrocarbon Hydroxylases; Bile; Cholesterol, HDL; Cholesterol, LDL; | 1986 |
Probucol inhibits oxidative modification of low density lipoprotein.
Topics: Animals; Cells, Cultured; Copper; Endothelium; Female; Humans; Hypercholesterolemia; Lipid Peroxides | 1986 |